INVO Fertility Shares Drop Amid Acquisition Agreement and Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 26 Jan 26
Source: Benzinga
INVO Fertility Inc. shares fell 14.78% to $2.02 after hitting a 5-day low, reflecting market uncertainty following recent acquisition news.
The company signed a definitive purchase agreement to acquire Family Beginnings, P.C. for $750,000, which includes $350,000 in cash and $400,000 in preferred stock. This acquisition is expected to close by February 27, 2026. Despite reporting a 23% year-over-year revenue increase to $1,757,094 in Q3 2025, INVO faced a net loss of $2.6 million, indicating ongoing financial challenges.
The decline in stock price amidst the acquisition news suggests cautious investor sentiment, as the company has seen a significant drop of 98.25% in stock value over the past year, trading near its 52-week low.
Analyst Views on IVF
About IVF
INVO Fertility Inc., formerly NAYA Biosciences, Inc., is a healthcare services company focused on the fertility marketplace and expanding access to assisted reproductive technology (ART) care for patients in need. Its segments include Fertility Clinic Services, INVOcell Device, and Therapeutics. It focuses on operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by its INVOcell medical device (INVOcell) and United States-based, in vitro fertilization (IVF) clinics. It has two operational INVO Centers in the United States and one IVF clinic. It is also engaged in the sale and distribution of its INVOcell technology solution to third party-owned and operated fertility clinics. The INVOcell is a proprietary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a natural, intimate, and affordable experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
